We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Advanced Melanoma

Journal Scan / Research · August 31, 2021

Cost-Effectiveness of Adjuvant Therapy for BRAF-Mutant Resected Stage III Melanoma

Annals of Surgical Oncology

 

Additional Info

Annals of Surgical Oncology
Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage 3 Melanoma in Medicare Patients
Ann. Surg. Oncol 2021 Jun 15;[EPub Ahead of Print], SA Mojtahed, NR Boyer, SA Rao, TF Gajewski, J Tseng, KK Turaga

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading